Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 6541 泰福-KY. Please read: https://finlab.finance/en/setup?stock=6541

No install, open FinLab Studio

6541

泰福-KY Biotech & Healthcare As of 2026-06-17 Updated daily after market close

quality needs a look, fair valuation.

1 active signal
Revenue ≥20%
This page refreshes daily after the close. Add 泰福-KY to your watchlist to track signal changes on your next visit.
Valuation 31Quality 2Growth 96Momentum 18Chips 69

Is 泰福-KY a buy? Fundamentals and valuation first

  • Weak profitability.Operating margin is in the 2th market percentile. Latest quarterly ROE ≈ -7.0%.

  • Foreign investors are net buying.Foreign 20-day net flow ≈ 3.1% of volume (net buy).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 208.2%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Neutral +0.13
BearishNeutralBullish

Institutional rotation, concentration steady — neutral

  • Institutional rotation, concentration steady — neutral
  • 新光 holds 776 lots
  • sellers have 162 lots left, ~58 sessions to clear

Window from 2026-01-17 · Price -22% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 新光 has accumulated 776 lots since the start (sold 2%), still adding.
  • Main distributor 永豐金-中和 peaked at 95 lots, has sold 32%, 65 left, paused recently.
  • TDCC big holders (absolute) >1000-lot holders -0.99pp, mid holders +4, retail -0.45pp — little change.
  • Foreign hedge-desk net short Net short -2,283 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
新光第一金-自由摩根大通統一-三多兆豐-復興元大-桃園
Distributing
永豐金-中和國泰-台中群益金鼎-古亭兆豐-天母合庫-西台中玉山-高雄
Desks
own scale
美林凱基-台北美商高盛元大-敦化
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 新光 +776
    sold 2%· still adding
  • 第一金-自由 +520
    sold 0%· still adding
  • 摩根大通 +428
    sold 0%· still adding
  • 統一-三多 +295
    sold 0%
  • 兆豐-復興 +267
    sold 0%
  • 元大-桃園 +195
    sold 0%· still adding

Distributing

  • 永豐金-中和 65 left
    sold 32%· paused recently
  • 國泰-台中 58 left
    sold 27%· paused recently
  • 群益金鼎-古亭 51 left
    sold 35%· ~27 sessions to clear
  • 兆豐-天母 42 left
    sold 45%· paused recently
  • 合庫-西台中 44 left
    sold 33%· paused recently
  • 玉山-高雄 10 left
    sold 83%· paused recently

Desks

  • 美林 -1,334
    hedge desk · will cover
  • 凱基-台北 -735
    day-trade · selling pressure
  • 美商高盛 -439
    hedge desk · will cover
  • 元大-敦化 -415
    day-trade · selling pressure
Still selling 162 lots ~58 sessions to bottom at most
Recent buy/sell force +502 absorbed / -102 sold buyers slightly ahead
Hedge-desk net short -945 lots potential cover-buying, not selling pressure
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Mixed direction: big-holder and retail changes are not aligned.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 208.2%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

32 historical occurrences (since 2022-09-12)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 35.5%, Sample 31, Median -4.76%, Excess -3.79%, Beat mkt rate 32.3%；60-day: Win 24.1%, Sample 29, Median -11.28%, Excess -18.46%, Beat mkt rate 17.2%；120-day: Win 19.2%, Sample 26, Median -14.62%, Excess -30.57%, Beat mkt rate 15.4%

120 days after: historical avg -12.34%

20-day -1.23%
60-day -9.04%
120-day -12.34%
20-day
60-day
120-day
Win
35.5%
24.1%
19.2%
Sample
31
29
26
Median
-4.76%
-11.28%
-14.62%
Excess
-3.79%
-18.46%
-30.57%
Beat mkt rate
32.3%
17.2%
15.4%

Over 26 occurrences, 120-day forward avg declined 12.34%, lagged the market by 30.57 pts; win rate 19.2%.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

30 times historically; 60-day forward avg -7.83%, win rate 27.6%, beating the market by -15.16 pts on average.

What does 泰福-KY do? Company profile

生技醫療業／生物製劑CDMO與生物相似藥 台灣證券交易所上市

Overview

6541 對應證券為泰福-KY，係在台灣證券交易所第一上市之外國發行人普通股，非 ETF、ETN、權證或特別股。上市公司主體為泰福生技股份有限公司（Tanvex BioPharma, Inc.），註冊地為開曼群島，主要營運據點包括台灣竹北與美國聖地牙哥。公司基本資料顯示成立日為2013/05/08，掛牌上市日為2017/10/26；部分公司新聞稿以2011年描述泰福生技事業起源，本文以交易所與年報之上市公司成立資料為準。董事長為盛保熙，總經理／執行長為 Stephen Lam，股務代理為中國信託商業銀行。2026年股東會年報列示截至2026/04/06普通股流通在外264,986,367股、股本約新台幣26.4986億元；截至同日員工合計220人，平均年齡41.61歲、平均服務年資5.35年。主要股東包括保瑞藥業股份有限公司79,043,981股、持股29.83%，鵬霖投資有限公司8.88%，Tanvex Biologics, Inc. 4.76%，Allen Chao and Lee Hwa Chao Family Trust 3.49%，匯弘投資2.53%，宜泰投資2.42%，潤泰全球2.37%，盛成投資2.14%，台新健康有限合夥1.89%，Delos Capital Fund, LP 1.81%。2025/01/20 泰福完成與保瑞集團旗下保瑞生技之策略整合，保瑞藥業成為單一最大法人股東。

Business

泰福的營運已由原本以自有生物相似藥研發、製造與銷售為核心，轉向以大分子生物藥 CDMO（委託開發暨製造服務）與生物相似藥商業化並行。主要服務包括細胞株開發與篩選、上游細胞培養、下游純化、分析方法建立、製程開發與放大、臨床與商業化量產、製劑開發與生產支援；產品類型涵蓋蛋白質類生物藥、抗體及抗體相關生物藥，應用於腫瘤、自體免疫、支持性治療及其他重大疾病。自有產品方面，TX01／NYPOZI 為 Neupogen（filgrastim）生物相似藥，已取得加拿大及美國上市相關許可，加拿大由 Sandoz 經銷，美國由 Cipla 旗下 Invagen Pharmaceuticals 負責行銷銷售，Tanvex USA 負責量產供應；TX05 為 Herceptin（trastuzumab）生物相似藥，2025年1月收到 FDA CRL，年報稱已於2025年12月向 FDA 遞交 BLA 申請，仍待審查結果。2025年度合併營收新台幣400,971千元，年增1056.27%；其中委託服務收入209,881千元，約占2025營收52.34%，其餘為銷貨收入、權利金收入及其他營業收入。2025年主要銷貨客戶以年報代號揭露，G公司占28.25%、D公司占19.09%、F公司占13.12%，其他占39.54%，真實名稱未公開。

Outlook 2025–2028

2025年為公司轉型關鍵年，TX01 進入美國市場並帶動產品銷售、權利金、里程碑及分潤機會，同時保瑞生技併入後強化竹北早期開發與美國聖地牙哥商業量產的端到端 CDMO 平台。2026年重點為推進 TX05 藥證取得、深化保瑞生技整合、提高 CDMO 接案與產能利用率；聖地牙哥廠新增2座2,000升一次性生物反應器，年報稱擴建已於2026年第1季如期完成，商業量產產能提升至8,000升。2026至2028年成長動能主要來自：美國在地生物製劑製造需求、全球藥廠委外開發與製造趨勢、BIOSECURE 法案及供應鏈去風險可能帶來中國以外 CDMO 機會、TX01 商業化放量、TX05 若獲准後的供貨需求、ADC／bioconjugation 技術平台與500升GMP批次等新服務。年報現金增資效益表列示 CDMO 專案預估銷售值：2026年新台幣297,000千元、2027年445,500千元、2028年1,089,000千元，屬公司募資計畫預估，非保證財測。主要風險包括：生物相似藥審查或查廠不確定性、TX05 CRL 回覆與核准時程、CDMO 專案型收入波動、客戶外包決策與資本支出循環、產能爬坡與品質合規風險、主要客戶或專案集中、長期虧損與資金需求、全球大型 CDMO 競爭，以及美國政策與藥價環境變動。

Supply Chain

Upstream
  • 戊公司 年報以代號揭露之2025年度主要供應商，進貨金額新台幣46,551千元，占年度進貨淨額23.69%；真實公司名稱未公開，是否上市櫃無法確認。
  • 己公司 年報以代號揭露之2025年度主要供應商，進貨金額新台幣28,596千元，占年度進貨淨額14.55%；真實公司名稱未公開，是否上市櫃無法確認。
  • 蛋白質純化介質、濾芯、培養袋、化學材料與一般耗材供應商群 公司年報稱主要採購具專利之原物料與耗材，供應狀況正常且未有集中交易；個別供應商名稱多未公開。
Downstream
  • Cipla／Invagen Pharmaceuticals, Inc. 非台股掛牌；Cipla 為印度跨國製藥公司，旗下美國子公司 Invagen 與 Tanvex USA 簽署 NYPOZI 美國市場授權、銷售暨製造協議，Cipla 負責美國行銷與銷售，Tanvex USA 負責量產供應。
  • Sandoz 非台股掛牌；TX01 加拿大市場經銷合作夥伴，負責加拿大上市銷售與市場滲透。
  • 全球生物製藥與生技公司客戶群 多數未公開名稱；年報稱竹北廠過去兩年完成超過35個 CDMO 客戶服務且準時交付比例100%，2025年主要銷貨客戶以 G、D、F 公司等代號揭露。

Competitors

  • 台康生技 6589 台股上市公司；同樣採 CDMO 與生物相似藥開發雙主軸，為台灣生物藥 CDMO 與生物相似藥主要競爭者。
  • 永昕生物醫藥 4726 台股上櫃公司；專注生物製劑與生物相似藥 CDMO，提供製程開發至 cGMP 生產之一站式服務，與泰福在生物製劑 CDMO 領域競爭。
  • Lonza Group 瑞士上市公司，全球大型生物製劑 CDMO，具規模、技術與國際客戶優勢；非台股掛牌。
  • Samsung Biologics 韓國上市公司，全球大型生物製劑 CDMO，與 Lonza、WuXi Biologics 等在大型生物製造外包市場競爭；非台股掛牌。
  • WuXi Biologics 香港上市公司，全球生物製劑 CDMO 重要業者；BIOSECURE 等政策變化可能使中國以外業者受惠，但其仍為全球競爭標竿；非台股掛牌。
Sources（10）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.